相关实验视频

Updated: Jul 6, 2026

PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS

PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS

Published on: December 27, 2013

葡萄细胞外-囊衍生纳米药物加载三功能 ((IV) 结合剂具有增强准和TME调节性质

Yan Chen¹, Shuaiqi Feng¹, Lanjie Li²

¹Institute of Biopharmaceutical Research, State Key Laboratory of Macromolecular Drugs and Large-scale Preparation, Shandong Provincial Key Laboratory of Applied Technology for Protein and Peptide Drugs, Liaocheng University, Liaocheng 252059, P. R. China.

Journal of medicinal chemistry

|May 26, 2025

概括

葡萄的细胞外囊泡 (GEVs) 携带 (IV) 结合物重新编程瘤微环境 (TME). 这种纳米药物减少了炎症,纤维化和免疫抑制,将冷瘤转化为热瘤,用于增强免疫疗法.

科学领域:

生物医学工程生物医学工程
纳米技术纳米技术
癌症治疗癌症治疗

背景情况:

瘤微环境 (TME) 是有效治疗癌症的复杂障碍.
调节TME的炎症性,纤维性和免疫抑制性特征对于改善治疗结果至关重要.

研究的目的:

开发一种新型纳米药物,Tf-GEVs@Pt(IV),用于有针对性的输送和TME调制.
为了研究这种多功能纳米药物在改变TME的治疗疗效.

主要方法:

制造葡萄细胞外囊泡 (GEVs),装有 ((IV) 结合物,并与转移素 (Tf) 功能化.
在体外和体内对纳米药物透,向和有效载荷释放在TME内的评估.
对纳米药物对炎症标志物 (COX-2,TNF-α,IL-6),纤维化 (TGF-β1,MMP2,MMP9) 和免疫细胞表型 (PD-L1,cGAS/STING,T细胞,M2/M1巨细胞) 的影响进行评估.

主要成果:

Tf-GEVs@Pt(IV) 证明了瘤透和向的增强.
持续释放的 (IV) 合物,产生 (II),阿司匹林 (ASP) 和 (CTP) 片段.
显著减少TME炎症和纤维化.
通过PD-L1抑制和cGAS/STING通路激活,免疫抑制TME转化为免疫热状态.
促进T细胞激活和M2到M1巨细胞两极分化.

结论:

Tf-GEVs@Pt(IV) 通过同时解决炎症,纤维化和免疫抑制,有效地重编程瘤微环境.
这种多方位的方法将"冷"瘤转化为"热"瘤,增强抗瘤免疫力,并为癌症治疗提供了一个有希望的策略.

更多相关视频

Synthesis of Functionalized 10-nm Polymer-coated Gold Particles for Endothelium Targeting and Drug Delivery

Synthesis of Functionalized 10-nm Polymer-coated Gold Particles for Endothelium Targeting and Drug Delivery

Published on: January 15, 2018

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods

Published on: May 11, 2018

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...